DrugPatentWatch Database Preview

Abbvie Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has ninety approved drugs.

There are eighty-nine US patents protecting ABBVIE drugs.

Summary for Abbvie

US Patents:	89
Tradenames:	78
Ingredients:	65
NDAs:	90
Drug Master File Entries:	1
Patent Litigation for Abbvie:	See patent lawsuits for Abbvie

Drugs and US Patents for Abbvie

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	PLACIDYL	ethchlorvynol	CAPSULE;ORAL	010021-007	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbvie	ULTANE	sevoflurane	LIQUID;INHALATION	020478-001	Jun 7, 1995	AN	RX	Yes	Yes	6,074,668*PED				Y
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-002	Nov 5, 2004	AB	RX	Yes	Yes	6,277,405			Y
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-001	Nov 5, 2004	AB	RX	Yes	No	7,041,319		Y
Abbvie	VICODIN	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	088058-001	Jan 7, 1983		DISCN	No	No
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		RX	Yes	Yes	8,685,984

Expired US Patents for Abbvie

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	MAVIK	trandolapril	TABLET;ORAL	020528-002	Apr 26, 1996	4,933,361
Abbvie Endocrine Inc	LUPRON DEPOT-PED	leuprolide acetate	INJECTABLE;INJECTION	020263-006	Jan 21, 1994	4,954,298
Abbvie	DEPAKOTE	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	018723-003	Oct 26, 1984	5,212,326*PED
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-002	Nov 5, 2004	5,145,684
Abbvie Endocrine Inc	LUPRON DEPOT-PED	leuprolide acetate	INJECTABLE;INJECTION	020263-002	Apr 16, 1993	4,917,893
Abbvie Endocrine Inc	LUPRON DEPOT-PED	leuprolide acetate	INJECTABLE;INJECTION	020263-004	Apr 16, 1993	5,575,987

Paragraph IV (Patent) Challenges for ABBVIE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	250 mg		2004-05-03
	Delayed-release Capsules	45 mg		2009-09-02
	Extended-release Tablets	2 mg/180 mg and 2 mg/240 mg		2007-11-09
	Tablets	100 mg/25 mg		2008-12-23
	Extended-release Tablets	4 mg/ 240 mg		2007-07-24
	Tablets	100 mg		2010-12-21
	Tablets	400 mg and 600 mg		2010-05-10
	Injection	0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials		2008-11-28
	Tablets	145 mg		2007-10-19
	Capsules	4 mcg		2008-08-25
	Tablets	5 mg/200 mg		2005-05-27
	Gel	1.62%		2012-04-06
	Injection	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial		2009-08-04
	Extended-release Tablet	500 mg		2010-12-06
	Extended-release Tablets	500 mg		2005-02-08
	Delayed-release Capsules	135 mg		2009-09-01
	Extended-release Tablets	1 mg/240 mg		2008-02-20
	Oral Solution	80 mg/20 mg per mL		2014-06-19
	Tablets	1 mg, 2 mg and 4 mg		2004-10-04
	Capsules	100 mg		2012-10-31
	Tablets	48 mg		2008-07-01
	Capsules	1 mcg and 2 mcg		2008-10-14
	Tablets	2.5 mg/200 mg		2006-02-24
	Gel Metered-dose Pump	1%		2008-12-19
	Gel	1.62% (1.25 g and 2.5 g packets)		2013-06-19
	Injection	2 mg/mL, 10 mL vial		2009-08-12

International Patents for Abbvie Drugs

Country	Document Number	Estimated Expiration
Slovenia	1313482
Turkey	200402549
Spain	2383954
Argentina	093924
Portugal	1313482
European Patent Office	1315502

Supplementary Protection Certificates for Abbvie Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB10/012	United Kingdom		PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
/2017	Austria		PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 (MITTEILUNG) 20170728
C/GB01/044	United Kingdom		PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
2203431/01	Switzerland		BEI DER ANMELDUNG WURDE DER INHABER IRRTUEMLICH DOPPELT ERFASST.
2017 00049	Denmark		PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728
C/GB95/010	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Abbvie
• Abbvie Endocrine
• Abbvie Endocrine Inc
• Abbvie Inc